Quick Answer
Ultragenyx Pharmaceutical Inc. reported Net Income of -$575.00 million for fiscal year 2025.
Ultragenyx Pharmaceutical Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$575.00M | -1.1% |
| 2024 | -$569.00M | +6.3% |
| 2023 | -$607.00M | +14.2% |
| 2022 | -$707.42M | -55.8% |
| 2021 | -$454.02M | -143.4% |
| 2020 | -$186.57M | +53.7% |
| 2019 | -$402.73M | -103.8% |
| 2018 | -$197.61M | +34.6% |
| 2017 | -$302.14M | -22.9% |
| 2016 | -$245.87M | -68.8% |
| 2015 | -$145.62M | -143.5% |
| 2014 | -$59.80M | -70.5% |
| 2013 | -$35.07M | -114.7% |
| 2012 | -$16.33M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$180.41M | -35.1% | -56.9% |
| June 30, 2025 | -$114.95M | +12.6% | +23.9% |
| March 31, 2025 | -$151.08M | +11.5% | -13.2% |
| September 30, 2024 | -$133.52M | +16.4% | -1.5% |
| June 30, 2024 | -$131.60M | +17.7% | +22.9% |
| March 31, 2024 | -$170.68M | -4.1% | -6.9% |
| September 30, 2023 | -$159.65M | +34.9% | +0.1% |
| June 30, 2023 | -$159.83M | -1.1% | +2.5% |
- Ultragenyx Pharmaceutical Inc. showed a decrease of -1.1% in Net Income compared to the prior fiscal year.
- Over the 2012–2025 period, Ultragenyx Pharmaceutical Inc.’s net income has declined by 3420.3% (from -$16.33 million to -$575.00 million).
- The most recent figure is from Ultragenyx Pharmaceutical Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: